Glibenclamide

Glibenclamide is an oral antidiabetic medicine that the ChEMBL database files under the name glyburide. ChEMBL records it as a small molecule whose mechanism is a blocker of sulfonylurea receptor 1 and the Kir6.2 channel, with approved indications of diabetes mellitus and type 2 diabetes mellitus. It gives the first approval as 1984 and the highest development phase as 4, which means it has reached the market, and the World Health Organization classification places it at ATC code A10BB01 in the alimentary tract and metabolism group. The adopted name dates from 1969. ChEMBL records it as an oral product and carries no boxed warning for it. This entry records what the sources state and is not medical advice.